Targeting ELOVL6 to disrupt c-MYC driven lipid metabolism in pancreatic cancer enhances chemosensitivity

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a 12% survival rate, highlighting the need for novel therapies. c-MYC overexpression, driven by upstream mutations and amplifications, reprograms tumor metabolism and promotes proliferation, migration and metastasis. This study...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ana García García, María Ferrer Aporta, Germán Vallejo Palma, Antonio Giráldez Trujillo, Raquel Castillo-González, David Calzón Lozano, Alberto Mora Perdiguero, Raúl Muñoz Velasco, Miguel Colina Castro, Elena de Simone Benito, Raúl Torres-Ruiz, Sandra Rodriguez-Perales, Jonas Dehairs, Johannes V. Swinnen, Juan Carlos Garcia-Cañaveras, Agustín Lahoz, Sandra Montalvo Quirós, Carlos del Pozo-Rojas, Clara Luque Rioja, Francisco Monroy, Diego Herráez-Aguilar, Marina Alonso Riaño, José Luis Rodríguez Peralto, Víctor Javier Sánchez-Arévalo Lobo
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2025-02-01
Series:	Nature Communications
Acceso en liña:	https://doi.org/10.1038/s41467-025-56894-8
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!